<?xml version="1.0" encoding="UTF-8"?>

<MedicinalProductDefinition xmlns="http://hl7.org/fhir">
  <id value="cfsb1151803027115"/>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative</b></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource "cfsb1151803027115" </p></div><p><b>identifier</b>: id: EU/1/16/1157/002 (OFFICIAL)</p><p><b>type</b>: Marketing Authorisation <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#100000072062)</span></p><p><b>domain</b>: Human use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#100000000012)</span></p><p><b>version</b>: 1</p><p><b>status</b>: Active <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://build.fhir.org/codesystem-publication-status.html">PublicationStatus</a>#active)</span></p><p><b>statusDate</b>: 2015-02-07T13:28:17Z</p><p><b>description</b>: Suliqua 100 units/ml + 50 microgram/ml solution for injection in a pre-filled pen:
Each pre-filled pen contains 300 units of insulin glargine* and 150 micrograms lixisenatide in 3 ml solution.
Each ml contains 100 units of insulin glargine and 50 micrograms lixisenatide.
Each dose step contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide</p><p><b>route</b>: Subcutaneous use <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#100000073633)</span></p><p><b>indication</b>: Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.</p><p><b>legalStatusOfSupply</b>: Medicinal product subject to medical prescription <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#100000072084)</span></p><p><b>classification</b>: insulin glargine and lixisenatide <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#A10AE54)</span>, Diabetes mellitus inadequate control <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#100000019249)</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen</p><p><b>type</b>: Full name <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#220000000001)</span></p><h3>NameParts</h3><table class="grid"><tr><td>-</td><td><b>Part</b></td><td><b>Type</b></td></tr><tr><td>*</td><td>Solution for injection</td><td>Pharmaceutical dose form part <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (#/#220000000005)</span></td></tr></table><h3>CountryLanguages</h3><table class="grid"><tr><td>-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td>*</td><td>European Union <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (unknown#eu)</span></td><td>European Union <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (unknown#eu)</span></td><td>English <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/3.0.0/CodeSystem-v3-ietf3066.html">Tags for the Identification of Languages</a>#en)</span></td></tr></table></blockquote></div>
  </text>
  <identifier>
    <use value="official"/>
    <system value="https://spor.ema.europa.eu/pmswi/#/"/>
    <value value="EU/1/16/1157/002"/>
  </identifier>
  <type>
    <coding>
      <system value="https://spor.ema.europa.eu/rmswi/"/>
      <code value="/#100000072062"/>
    </coding>
    <text value="Marketing Authorisation"/>
  </type>
  <domain>
    <coding>
      <system value="https://spor.ema.europa.eu/rmswi/"/>
      <code value="/#100000000012"/>
    </coding>
    <text value="Human use"/>
  </domain>
  <version value="1"/>
  <status>
    <coding>
      <system value="http://hl7.org/fhir/publication-status"/>
      <code value="active"/>
      <display value="Active"/>
    </coding>
  </status>
  <statusDate value="2015-02-07T13:28:17Z"/>
  <description value="Suliqua 100 units/ml + 50 microgram/ml solution for injection in a pre-filled pen:&#xA;Each pre-filled pen contains 300 units of insulin glargine* and 150 micrograms lixisenatide in 3 ml solution.&#xA;Each ml contains 100 units of insulin glargine and 50 micrograms lixisenatide.&#xA;Each dose step contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide"/>
  <route>
    <coding>
      <system value="https://spor.ema.europa.eu/rmswi/"/>
      <code value="/#100000073633"/>
    </coding>
    <text value="Subcutaneous use"/>
  </route>
  <indication value="Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors."/>
  <legalStatusOfSupply>
    <coding>
      <system value="https://spor.ema.europa.eu/rmswi/"/>
      <code value="/#100000072084"/>
    </coding>
    <text value="Medicinal product subject to medical prescription"/>
  </legalStatusOfSupply>
  <classification>
    <coding>
      <system value="https://www.whocc.no/atc_ddd_index/"/>
      <code value="A10AE54"/>
    </coding>
    <text value="insulin glargine and lixisenatide"/>
  </classification>
  <classification>
    <coding>
      <system value="https://spor.ema.europa.eu/rmswi/"/>
      <code value="/#100000019249"/>
    </coding>
    <text value="Diabetes mellitus inadequate control"/>
  </classification>
  <name>
    <productName value="Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen"/>
    <type>
      <coding>
        <system value="https://spor.ema.europa.eu/rmswi/"/>
        <code value="/#220000000001"/>
      </coding>
      <text value="Full name"/>
    </type>
    <namePart>
      <part value="Solution for injection"/>
      <type>
        <coding>
          <system value="https://spor.ema.europa.eu/rmswi/"/>
          <code value="/#220000000005"/>
        </coding>
        <text value="Pharmaceutical dose form part"/>
      </type>
    </namePart>
    <countryLanguage>
      <country>
        <coding>
          <system value="urn:iso:std:iso:3166"/>
          <code value="eu"/>
        </coding>
        <text value="European Union"/>
      </country>
      <jurisdiction>
        <coding>
          <system value="urn:iso:std:iso:3166"/>
          <code value="eu"/>
        </coding>
        <text value="European Union"/>
      </jurisdiction>
      <language>
        <coding>
          <system value="urn:ietf:bcp:47"/>
          <code value="en"/>
        </coding>
        <text value="English"/>
      </language>
    </countryLanguage>
  </name>
</MedicinalProductDefinition>